Autologous Dendritic Cell Vaccine in Kidney Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Carcinoma, Renal Cell
Interventions
BIOLOGICAL

Autologous alpha-DC1/TBVA vaccine

"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."

DRUG

Cabozantinib

Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.

Trial Locations (1)

15232

RECRUITING

UPMC Department of Urology, Pittsburgh

All Listed Sponsors
lead

Jodi Maranchie

OTHER